Stem Cell Network and Capital BioVentures Announce a Strategic Partnership to Drive Canadian Regenerative Innovations Forward

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

The Stem Cell Network (SCN) and Capital BioVentures (CBV) recently announced a new partnership to accelerate the development and commercialization of regenerative medicine innovations in Canada. Through this strategic collaboration, emerging regenerative medicine biotechs will receive business advisory support and funding to advance their intellectual property, strengthen commercialization strategies, and attract investment.

Stem Cell Network is OBIO's partner to enhance the commercialization of life science innovations through specialized training for scientists. Capital BioVentures is an OBIO® member.

Arsheen Kaur
Next

Afynia Laboratories Closes $5M Seed Round, Proceeds to Help Revolutionize Endometriosis Care